PaPE-1 is a pathway-preferential estrogen that activates extracellular nuclear signaling pathways without affecting nuclear signaling pathways. It exerts anti-apoptotic effects by inhibiting Aβ-induced caspase activity and reducing chromatin condensation associated with apoptosis, thereby preventing neuronal cell death. Additionally, post-treatment with PaPE-1 decreases the mRNA expression of apoptosis-specific factors (such as Bax, Gsk3b, Fas, and Fasl) under Aβ influence, while upregulating Bcl2 expression.